News and Trends 3 Aug 2022 AbCellera and Atlas Venture to collaborate on new company for therapeutic antibody discovery …transforming innovative scientific research into exciting new biotechs,” said Carl Hansen, CEO and president of AbCellera. “By eliminating their need to build internal antibody discovery capabilities at inception, we provide… August 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2025 Top biotech deals in July 2025 …IGM Biosciences and iTeos Therapeutics, both of which experienced significant lows this year. The $82 million deal with IGM came after the antibody developer was ditched by Sanofi in May,… August 8, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
More News! 20 Jun 2017 Belgian Llama Antibody Developer gets Second Preclinical Milestone from Danish Pharma …ARGX-112, though an amount has not been disclosed. The antibody, indicated for inflammatory skin diseases, was discovered with the biotech’s SIMPLE discovery platform. The Belgian biotech will carry out preclinical… June 20, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 9 Oct 2017 The Woman Developing the Next Generation of Cancer Immunotherapy …so far and putting its unique antibody technology one step closer to patients. As she continues at Ganymed by supporting the new owners in their takeover of late-stage antibody development,… October 9, 2017 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Mar 2017 Which European Blockbusters Topped the Charts in 2016? …is a monoclonal antibody used to treat breast cancers, which are HER2–positive. The antibody binds to the HER2 receptor overexpressed on some breast cancers, thereby inhibiting the proliferation of these… March 8, 2017 - 4 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 14 Dec 2017 New Biotech in Oxford Takes on Arthritis of the Spine …for the trial, expected to start in the first half of 2018. Namilumab is a human antibody that targets granulocyte macrophage-colony stimulating factor (GM-CSF). The antibody was originally developed by… December 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 Pictor receives $5M in funding for Covid antibody test and human and animal portfolios …company announced it had received confirmation of CE registration for its PictArray SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) antibody test as per in vitro diagnostic directive (IVDD) regulations. CE registration… December 6, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2022 Collaboration to develop new glioblastoma combination therapy nets €1.06M …by Amsterdam UMC and will help CimCure to study passive immunization. Additionally, Covalab will develop full-length and antibody fragments, to be used for CAR-T cells. This novel approach to antibody… September 20, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2017 French Biotech Strikes Deal with Novo Nordisk for New Cancer Drug …Pharma has in-licensed a new clinical-stage antibody candidate from Novo Nordisk to reinforce its position in the crowded space. In exchange for its anti-C5aR antibody, IPH5401, Novo Nordisk gets a… June 6, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Interview 24 Jul 2018 Meet the Dutch Scientists who Invented Keytruda, “The President’s Drug” …form of antibody, Keytruda blocks the cancer cells’ ability to hide from the immune system. In melanoma patients treated with the drug, tumors are more likely to shrink compared to… July 24, 2018 - 6 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
Weekly Roundup 15 Dec 2023 Pharvaris’ $300 million public offering; Genentech’s breast cancer trial success; new neuromuscular disease target discovered …Squibb to collaborate to develop cancer treatment Antibody therapy company SystImmune is collaborating with Bristol Myers Squibb (BMS) to develop and commercialize BL-B01D1, a bispecific antibody-drug conjugate (ADC). The candidate… December 15, 2023 - 14 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 6 Apr 2020 UK Biotech’s Arthritis Drug Enters Study in Coronavirus Patients …we can prevent or reduce deterioration in Covid-19 patients for which there are currently few treatments available.” Izana’s antibody therapy is a human monoclonal antibody targeting GM-CSF and is in… April 6, 2020 - 2 minutesmins - By David Kirk Share WhatsApp Twitter Linkedin Email